Overview

Preparing a healthier Tomorrow

Clonal Hematopoiesis is a syndrome in which cancer related mutation occur and blood cells containing the
mutation spreads so that more than 2% of the blood cells have the mutation.

As people age, the cells in peoples’ bodies accumulate random mutations, drastically improving clonal
hematopoiesis.¹

If clonal hematopoiesis occurs, the chance of blood cancer and diseases related to cardiovascular system
drastically increases over that of a healthy individual.

Overview 이미지
Overview 이미지

What is a Blood-C RISK ?

Blood-C Risk tests for Clonal Hematopoiesis,
which is related to increased risks of blood cancer and Cardiovascular diseases

Blood-C RISKis SD Genomics’ clinical diagnostics test based on NGS(next-generation-sequencing),
using the DNA extracted from blood cells to find clonal hematopoiesis and high-risk group.

Blood-C RISKtests for the frequently found variants in genes from the results of a large-scale clonal
hematopoiesis study done with a 31-gene panel. After analyzing the DNA extracted from blood cells, if
mutations of 2% or higher have been found in any of the 31 genes, such results are reported as clonal
hematopoiesis.

Blood-C RISK 이미지

Detectable Diseases

Only one test to know the risk of clonal hematopoiesis and cardiovascular disease

When clonal hematopoiesis occurs, the chance of blood cancer incidence increases 11 to 13 times
higher than those without, and risk for coronary artery diseases, ischemic stroke, and early myocardial
infarction occurring before age 50, increases by 2~4 times.

Also, the risk for secondary myeloid leukemia increases by 13 ~ 14 times.

이미지 1-2 1.3

To whom is the test useful to?

Know your risk 검사대상 이미지
  • Middle aged people who want to know their risk of Blood Cancer incidence.
  • People with minor blood cell count reduction with unknown reasons, or with any abnormal blood test results
  • Those who went through or is planning on going through cancer treatment and radiation treatment.
  • Middle aged people who want to know their risk of coronary artery disease or early-onset myocardial infarction

Test Procedure

SD Genomics is a reliable genetic testing service company

SD Genomics performs genetic tests to the requests of medical institutes following the Bioethics and Safety Act. Prior to service request,
understanding the objective of the test, reporting method of the test, and limitations of the test is necessary.

검사절차 이미지
Hospital
Draw Blood at the hospital.
The Test receives information and fills out the
‘Genetic Test Consent’ form.
The hospital’s staff fills out “Genetic Test Request
form”.
SD Genomics
SD Genomics receives the samples and required
forms.
SD genomics performs the requested test and
analyzes its results.
SD Genomics fills out the test report and sends it
Hospital
After receiving the report, the hospital dose the
genetic counselling.

Test info

Specimen
requirement
  • Whole blood (3-5 cc EDTA tube)
  • DNA 5 - 10 ug TE buffer(min. density 50 ng/uL, A260/A280 ratio: 1.65-2.0)
Sample Logistics
  • Whole Blood or DNA 15-30 ℃ room temperature(within 24 hours) 2-8 ℃ refrigerated (within 7 days)
Required Documents Test Requirement and Consent form (provided below)
TAT Within 4-6 weeks
Report Criteria We test the coding exon region of 31 genes reported to be associated with clonal hematopoiesis. All genes and genetic
variations in the test is selected on large-scale studies or on public databases and reported if ratio in which the variant
is found is more than 2%.

Resources

References
1. Jaiswal et al., Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes, N Engl J Med 2014;371:2488-2498.
2. Genovese et al., Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence, N Engl J Med 2014;371:2477-2487.
3. Jaiswal et al., Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease, Lancet Oncol 2017;377:111-121.
4. Takahashi et al., Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study, Lancet Oncol 2017;18:100-111.